In recent years, HER2-low breast cancer, characterized by HER2 IHC scores of 1 + or 2 + along with a ISH- result, has become eligible for treatment with trastuzumab deruxtecan (T-DXd) based on the results of the DESTINY-Breast04 trial [5]. The gene discussed is ERBB2; the disease is breast carcinoma.